Kunena :: Тема: Posted by Elinor Pyle on 29.11.2016 9:02:59: side effects with tarceva (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Elinor Pyle on 29.11.2016 9:02:59: side effects with tarceva

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Elinor Pyle on 29.11.2016 9:02:59: side effects with tarceva

Страница:
1
2

ТЕМА: Posted by Elinor Pyle on 29.11.2016 9:02:59: side effects with tarceva

Posted by Elinor Pyle on 29.11.2016 9:02:59: side effects with tarceva 8 года 4 мес. назад #910

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.
The fact that combination of oHSV with erlotinib did not show enhancement of the antitumor effect may be explained by a number of non-exclusive hypotheses. First, a higher dose of erlotinib may be required to observe any enhancement of the oHSV-mediated antitumor effect. Although some investigators have shown higher efficacy of erlotinib in non-MPNST preclinical models using higher doses, 36 in our experiments we chose to administer erlotinib at a clinically relevant dose of 25 mg/kg/day. This dose predicts a similar "area under the curve" (1,396 day-ng/mL in mice given 20 mg/kg/day) as that achievable in humans (1,520 day-ng/mL in humans given 150 mg daily). 36. 37 Another explanation for the lack of a combination effect could be that the dramatic antitumor effect of oHSV overshadowed the relatively modest erlotinib effect; therefore, administration of a lower dose of oHSV may reveal an additive effect of erlotinib. It is also possible that MPNST xenografts treated with erlotinib had acquired resistance to erlotinib or lost dependence upon EGFR signaling. In that case, other factors could bypass a need for EGFR-mediated signaling.
Another potential strategy is the use of immune checkpoint inhibitors such as programmed death (PD)-1 pathway inhibitors, which have drawn much attention in recent years. Preclinical studies demonstrated that mutant EGFR signaling drives expression of programmed death-ligand 1 (PD-L1) and that blockade of the PD-1 receptor improved survival of mice with EGFR -mutant tumors. 82 Preliminary results of a study investigating the combination of nivolumab (anti-PD-1 monoclonal antibody) and erlotinib reported an ORR of 19% (four of 21 patients, with three of four responders having previously progressed while receiving erlotinib). 83 Nivolumab has been recently approved by the FDA for the treatment of patients with squamous NSCLC after failure of chemotherapy. Further investigations of nivolumab as monotherapy or in combination with EGFR TKI in patients with NSCLC and EGFR mutations will provide further insight into the role of immunotherapy (NCT02323126 ).
After screening and enrolment, patients received four cycles of induction chemotherapy (cisplatin 80 mg/m 2 day 1 plus gemcitabine 1,250 mg/m 2 day 1, day 8 of a 3-week cycle). Disease status was reassessed after completion of four treatment cycles; patients without evidence of disease progression or unacceptable toxicity were then randomly assigned in a 1:1:1 ratio to observation (control arm), continuation maintenance with gemcitabine (1,250 mg/m 2 day 1, day 8 of a 3-week cycle), or switch maintenance with erlotinib (150 mg/d). Maintenance treatment was continued until disease progression, unacceptable toxicity, or death. On disease progression, patients in all three treatment arms received pemetrexed (500 mg/m 2 every 21 days) as predefined second-line therapy with vitamin B12/folic acid supplementation and corticosteroid premedication. Our study was designed and conducted before the labeling restriction of pemetrexed to nonsquamous cell carcinoma.
Common side effects of Tarceva include but are not limited to:
amceramica.ru/index.php?option=com_kunen...=8&id=21848&Itemid=0
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Gatekeeper mutant AXL p.Leu350Met. XL-880 inhibition X(sensitivity restore X) AXL Kinase activity is necessary for resistance AXL-mediated resistance may occur during EMT siRNA-mediated knockdown of VIM Vimentin O/E is necessary for R? Not completely abolish AXL expression and Vimentin AXL is associated with EMT for resistance to erlotinib Clinical validation of the theory AXL upregulation in clinical specimens Recent studies AXL & EMT(Histological change) EMT & resistance Conclusion AXL activation is required for erlotinib-resistance in NSCLC 1. Overexpression in vivo & in vitro models 2. Inhibition of AXL makes ERs to be sensitive 3. Forced overexpression also induces resistance 4. AXL activates MAPK, AKT, and NF-kB 5. AXL is associated with EMT
taekwondo52.ru/forum/8--/5732-posted-by-...ung-cancer.html#5732
Experimental: Erlotinib and Chemotherapy
Study of possible correlation between PERICARDITIS and ERLOTINIB HYDROCHLORIDE
www.facecool.com/profiles/blogs/posted-b...54-51-erlotinib-pd-1
We evaluated the long-term effect of erlotinib on LCSCs in colony formation assay. Erlotinib treatment dramatically reduced the ability of LCSCs with activated EGFR to generate colonies in soft agar assay, demonstrating long-term efficacy of the drug and its ability to target the clonogenic cells ( Figure 2d ). We next compared LCSC response with erlotinib and EGFR activation level with that of their in vitro differentiated counterpart ( Figures 2e and f ). In erlotinib-sensitive LCSCs, EGFR tyr1068 expression was more prominent in stem versus in vitro differentiated cell populations ( Figure 2f ). Consistent with the proposed role of EGFR tyr1068 in marking an EGFR-addicted functional state, erlotinib-induced cytotoxicity against LCSCs was even more marked than that observed in the differentiated cells ( Figure 2e ). In vitro differentiation was substantiated by reduction of embryonic gene expression (ALDH1, SOX2) and gain of chemosensitivity, as shown in Figures 1b and c and our previous data. 32. 33 In line with these results, drug treatment of the LCSC population determined a reduction of the stemness-related aldehyde dehydrogenase (ALDH) expression. Based on the assumption that tumor spheres are highly enriched in CSCs although containing cells with lower degree of stemness, these results confirm that erlotinib preferentially killed the more undifferentiated cells within the LCSC culture (Supplementary Figure 1B ).
The most frequent Grade 3-4 adverse reactions in TARCEVA-treated patients were rash and diarrhea.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
bus-rostov.ru/forum/razdel-predlozhenij/...eva-vs-gilotrif.html
Berlin (26. Februar 2010) - Beim fortgeschrittenen NSCLC zählt die zielgerichtete Therapie mit Erlotinib (Tarceva®) oder Bevacizumab (Avastin®) heute zu den etablierten Therapieoptionen und wird daher in der kürzlich publizierten interdisziplinären S3-Leitlinie empfohlen. Eine weitere Verbesserung der Therapieergebnisse lassen die beim Deutschen Krebskongress präsentierten Daten der SATURN (Sequential Tarceva in Unresectable NSCLC)-Studie erwarten. Danach profitieren nicht nur Patienten mit aktivierenden EGFR-Mutationen, sondern auch solche mit EGFR-Wildtyp von der First-Line-Erhaltungstherapie mit Erlotinib (1).
dnz2.rosvita.rv.ua/index.php/forum
4. Rouge, A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib, Cancer Research 67, 6253-6262, July 1, 2007
Sixty-five eligible adults with newly diagnosed GBM or gliosarcoma were enrolled. We intended to treat patients not currently treated with enzyme-inducing antiepileptic drugs (EIAEDs) with 100 mg/d of erlotinib during XRT and 150 mg/d after XRT. Patients receiving EIAEDs were to receive 200 mg/d of erlotinib during XRT and 300 mg/d after XRT. After XRT, the erlotinib dose was escalated until patients developed tolerable grade 2 rash or until the maximum allowed dose was reached. All patients received temozolomide during and after XRT. Molecular markers of epidermal growth factor receptor (EGFR), EGFRvIII, phosphatase and tensin homolog (PTEN), and methylation status of the promotor region of the MGMT gene were analyzed from tumor tissue. Survival was compared with outcomes from two historical phase II trials.
fsp.akipkro.ru/forum/soobshchestvo-bazov...ung-cancer-nejm.html
The solubility of Erlotinib is inversely proportional to pH i.e. high pH low solubility/low pH high solubility.
ubsk.com.ua/ru/forum/skrin-ka-propozitsi...rceva-rash-look-like
how does alcohol effect tarceva
Given the prominent importance of EGFR signaling in cancer development, both anti-EGFR monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitors have been developed. Anti-EGFR antibodies, eg. cetuximab and panitumumab, bind to the extracellular domain of EGFR monomer and compete for receptor binding by the endogenous ligands; in this way they block ligand-induced receptor activation. The small molecule EGFR inhibitors, such as erlotinib, gefitinib and lapatinib, compete with ATP to bind the catalytic domain of the kinase which in turn inhibits EGFR autophosphorylation and downstream signaling. However, these inhibitors are known to be effective in only a small subset of patients. Mutations in the EGFR gene and possible down-stream effectors have been shown to be associated with various clinical outcomes associated with EGFR inhibitor treatments [Articles:17375033. 17285735. 15118073. 15118125 ].